Search Result

Results for "

Aurora+A+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (15) Aurora Kinase (54) Autophagy (3) CDK (4) FAK (1) FLT3 (1) Ligands for Target Protein for PROTAC (1) p38 MAPK (1) PERK (1) Reactive Oxygen Species (ROS) (1) Reference Standards (6) VEGFR (1)
By Research Areas:	Cancer (54)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10127

Barasertib Maximum Cited Publications 25 Publications Verification AZD1152	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective *Aurora B* inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent *aurora kinase* inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, *aurora-A* and *aurora-B*, respectively .

HY-10179

Danusertib 5+ Cited Publications PHA-739358	Aurora Kinase Autophagy	Cancer
Danusertib is a pyrrolo-pyrazole and *aurora kinase* inhibitor with IC₅₀ of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-13253

AMG 900 4 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-14711

Reversine 15+ Cited Publications	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive *Aurora kinase* inhibitor with IC₅₀s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.

HY-10126

Barasertib-HQPA 5+ Cited Publications AZD2811; INH-34; AZD1152-HQPA	Aurora Kinase Apoptosis	Cancer
Barasertib-HQPA (AZD2811) is a highly selective *Aurora B* inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells .

HY-10128

ZM-447439 5+ Cited Publications	Aurora Kinase Apoptosis	Cancer
ZM-447439 is an *aurora* kinase inhibitor with IC₅₀s of 110 and 130 nM for aurora A and B, respectively.

HY-10558

CYC-116 4 Publications Verification	Aurora Kinase	Cancer
CYC-116 is a potent aurora A and *aurora B* inhibitor with K_is of 8 and 9 nM, respectively.

HY-12003

SNS-314 mesylate 3 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-137377

TAS-119 1 Publications Verification	Aurora Kinase	Cancer
TAS-119 is a potent, selective and orally active *Aurora A* inhibitor with an IC₅₀ of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC₅₀ of 95 nM). TAS-119 has potent antitumor activites .

HY-70061

TCS7010 2 Publications Verification	Aurora Kinase Apoptosis	Cancer
TCS7010 is a potent and highly selective *Aurora A* inhibitor with with an IC₅₀ of 3.4 nM.

HY-10804

CCT 137690 1 Publications Verification	Aurora Kinase Apoptosis	Cancer
CCT 137690 is a potent and orally available *aurora* kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

HY-14574

PF-03814735 2 Publications Verification	Aurora Kinase VEGFR	Cancer
PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and *aurora B* inhibitor with IC₅₀s of 0.8 and 0.5 nM, respectively.

HY-10178

PHA-680632	Aurora Kinase	Cancer
PHA-680632 is an *aurora* kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and *Aurora kinase* inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive *Aurora kinase* inhibitor with IC₅₀s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC₅₀ of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

HY-12049

CCT129202	Aurora Kinase	Cancer
CCT129202 is an *aurora* kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

HY-144991

Aurora kinase inhibitor-8	Aurora Kinase	Cancer
Aurora kinase inhibitor-8 is a highly selective inhibitor of the Aurora kinases.

HY-10127A

Barasertib dihydrochloride AZD1152 dihydrochloride	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152 dihydrochloride), a pro-drug of Barasertib-hQPA, is a highly selective *Aurora B* inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152 dihydrochloride) induces growth arrest and apoptosis in cancer cells .

HY-162470

DBPR728	Aurora Kinase	Cancer
DBPR728 is an acyl prodrug of 6K465 that carries fewer hydrogen bond donors. 6K465 acts as an *Aurora* kinase inhibitor that destabilizes MYC family cancer proteins and has antitumor efficacy. DBPR728 has the potential to inhibit cancers that overexpress C-MYC and N-MYC, with a 10-fold increase in oral bioavailability compared to 6K465 .

HY-168440

Aurora-A ligand 1	Ligands for Target Protein for PROTAC Aurora Kinase CDK	Cancer
Aurora-A ligand 1 is a high-affinity and specific *Aurora-A* inhibitor with a dissociation constant (K_d) value of 0.85 nM. Aurora-A ligand 1 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC Aurora-A degraders with antitumor activity. Aurora-A ligand 1 can be used for the synthesis of HLB-0532259 (HY-168439). HLB-0532259 shows anti-tumor activity against neuroblastoma .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-175866

Aurora kinase-IN-8	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-8 is a orally active *Aurora kinase* inhibitor. Aurora kinase-IN-8 shows IC₅₀ values of 2.8 and 28.1 nM against Aurora A kinase and Aurora B kinase. Aurora kinase-IN-8 can prevent spindle formation, cause G2/M phase arrest, and induce cell apoptosis. Aurora kinase-IN-8 can be used for the research of cancer, such as triple-negative breast cancer .

HY-147703

Aurora kinase inhibitor-9	Aurora Kinase	Cancer
Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC₅₀s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .

HY-149693

Aurora kinase inhibitor-11	Aurora Kinase	Cancer
Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC₅₀ of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC₅₀ values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-N3737

Derrone	Aurora Kinase PERK Reactive Oxygen Species (ROS)	Cancer
Derrone, a prenylated isoflavones, is an *Aurora kinase* inhibitor, with IC₅₀ values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .

HY-146037

Aurora A inhibitor 2	Apoptosis Aurora Kinase	Cancer
Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC₅₀ of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells .

HY-156378

Aurora A inhibitor 3	Aurora Kinase	Cancer
Aurora A inhibitor 3 (Compound 5h) inhibits Aurora-A kinase with an IC₅₀ value of 0.78 μM. Aurora A inhibitor 3 is cytotoxic, with GI₅₀ values of 0.12 μM and 0.63 μM for MCF-7 and MDA-MB-231 cells, respectively .

HY-143713

Aurora A inhibitor 1	Aurora Kinase	Cancer
Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49) .

HY-10320G

Doramapimod (GMP) BIRB 796 (GMP)	p38 MAPK	Cancer
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC₅₀s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .

HY-169735

Aurora A inhibitor 4	Aurora Kinase	Cancer
Aurora A inhibitor 4 (compound C9) is a potent inhibitor of Aurora A, with the GI₅₀ of 4.26 and 7.08 μM in DU 145 cells and HT-29 cells, respectively .

HY-178343

Aurora A-IN-5	Aurora Kinase Apoptosis	Cancer
Aurora A-IN-5 is a potent and highly selective *Aurora A* inhibitor (IC₅₀ = 0.02 μM), showing 362-fold selectivity for over Aurora B. Aurora A-IN-5 shows its selectivity through unique C−H/π interactions, enhanced hydrophobic contacts, an open binding pocket, and tighter protein packing. Aurora A-IN-5 suppresses Aurora A autophosphorylation, thereby inhibiting cancer cell proliferation by inducing G2/M phase arrest, triggering apoptosis, and suppressing colony formation. Aurora A-IN-5 inhibits tumor growth in MDA-MB-231 xenograft mouse models. Aurora A-IN-5 can be used for breast, cervical, prostate, and lymphoma cancer research .

HY-147993

Aurora kinase inhibitor-10	Aurora Kinase	Cancer
Aurora kinase inhibitor-10 (Compound 6c) is an orally active *Aurora B* inhibitor with an IC₅₀ of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .

HY-U00304

Aurora B inhibitor 1	Aurora Kinase	Cancer
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a K_i value of <0.010 uM.

HY-113894

Retreversine	Aurora Kinase	Cancer
Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .

HY-149694

Aurora kinase inhibitor-12	Aurora Kinase	Cancer
Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth .

HY-125158A

(E/Z)-HOI-07	Aurora Kinase	Cancer
(E/Z)-HOI-07 is a potent and selective *Aurora B* inhibitor. HOI-07 has antitumor activity .

HY-169505

Aurora kinase inhibitor-13	Aurora Kinase	Cancer
Aurora kinase inhibitor-13 (Compound 2) is an inhibitor of Aurora kinase, with an IC₅₀ value of 2.3 μM against Aurora kinase A .

HY-123697

VE-465	Aurora Kinase	Cancer
VE-465 is an *Aurora kinase* inhibitor. VE-465 induces cancer cell apoptosis. VE-465 has anticancer effects in multiple tumor models .

HY-10179R

Danusertib (Standard) PHA-739358 (Standard)	Reference Standards Aurora Kinase Autophagy	Cancer
Danusertib (Standard) is the analytical standard of Danusertib. This product is intended for research and analytical applications. Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-122370A

Tripolin B	Aurora Kinase	Cancer
Tripolin B is an ATP-competitive *Aurora kinase* inhibitor with IC₅₀ values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells .

HY-160447

*FAK/Aurora* kinase-IN-1**	Aurora Kinase FAK	Cancer
FAK/Aurora kinase-IN-1 is a FAK and *aurora kinase* inhibitor with IC₅₀ values of 6.61 nM and 0.91 nM, respectively. FAK/Aurora kinase-IN-1 shows anticancer effects (WO2018019252A1; compound 11) .

HY-10127R

Barasertib (Standard) AZD1152 (Standard)	Reference Standards Aurora Kinase Apoptosis	Cancer
Barasertib (Standard) is the analytical standard of Barasertib. This product is intended for research and analytical applications. Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .

HY-15812

XMD-12	Aurora Kinase	Cancer
XMD-12 (compound 1) is an Aurora kinase (Aurora Kinase) inhibitor with anti-tumor activity that promotes paclitaxel (HY-B0015) induced cell death. XMD-12 exhibits high selectivity and potency against Aurora A, B, and C kinases, with IC₅₀ values of 5.6, 18.4, and 24.6 nM, respectively .

HY-170812

*BET/Aurora* kinase-IN-1**	Aurora Kinase	Cancer
BET/Aurora kinase-IN-1 (Compound 38) is a dual BET/Aurora kinase inhibitor. BET/Aurora kinase-IN-1 shows antiproliferative activities on diverse cancer cell lines and favorable antitumor efficacy in renal cell cancer and colon cancer xenograft models with tumor growth inhibition (TGI) of 45.99% and 53.06%, respectively .

HY-150592

Aurora kinase-IN-2	Aurora Kinase	Cancer
Aurora kinase-IN-2 (compound 12Aj) is a potent *Aurora kinase* inhibitor with IC₅₀ values of 90 and 152 nM for Aurora A and Aurora B. Aurora kinase-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora kinase-IN-2 can be used for cancer research .

HY-123279

OM137	Aurora Kinase CDK	Cancer
OM137 is an *aurora kinase* inhibitor, with an IC₅₀ of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC₅₀ of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes .

HY-10180A

MLN8054 sodium	Aurora Kinase	Cancer
MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aurora+A+inhibitor

Inhibitors & Agonists

NaturalProducts

Natural
Products